Breaking AI & Tech News Analyzed

The U.S. Food and Drug Administration announced on Wednesday that it has granted expedited approval to Eli Lilly’s oral weight‑loss medication, orforglipron—marketed under the brand name Foundayo. This makes Foundayo the second GLP‑1 pill to reach U.S. consumers, following Novo Nordisk’s Wegovy tablet approved in December. Orforglipron works by mimicking a natural hormone that regulates appetite and satiety, offering a non‑injectable alternative to existing GLP‑1 injectables. David A. Ricks, Eli Lilly’s chair and CEO, highlighted that fewer than one in ten eligible patients are currently using GLP‑1 therapies, citing barriers such as cost, stigma, and perceived complexity. Unlike Wegovy, which must be taken on an empty stomach each morning, Foundayo can be taken anytime of day regardless of meals, simplifying dosing schedules. Patients will start on a low dose that is gradually increased to mitigate side‑effects. Pricing is projected at $149 per month for the initial dose, with higher‑strength formulations potentially reaching $349 monthly. While private‑insurance coverage remains uncertain, a Trump‑administration proposal could allow Medicare to cover certain patients as early as this summer, with copayments as low as $50 per month. Distribution will commence on Monday through LillyDirect’s direct‑to‑consumer channel, with broader availability in pharmacies and telehealth platforms expected shortly thereafter. The convenience of a once‑daily pill is anticipated to improve adherence, especially for individuals who avoid injectables due to needle aversion or rigid dosing requirements. The approval follows a fast‑track submission submitted only months ago, positioning Foundayo to enter the market roughly three months after Wegovy. This rapid rollout is set to intensify competition in the burgeoning GLP‑1 space, where new agents are continually emerging with claims of better efficacy and lower costs.

The literary world is grappling with a new challenge: detecting AI-written books. Kate Nash, a literary agent, recently discovered an AI prompt at the top of a submission letter, which raised concerns about the use of artificial intelligence in book writing. The controversy surrounding Mia Ballard's 'femgore' horror novel Shy Girl, which was suspected to be up to 78% AI-generated, has forced literary agents and publishers to reevaluate their ability to detect AI-generated work. Hachette halted US publication of Shy Girl and removed it from online retailers after an internal review. Experts warn that AI detection tools are not foolproof and that the technology is advancing rapidly. Prof Patrick Juola, a US computer scientist, likens the failure of AI detection tools to antibiotic resistance, stating that AI is a learning system continually upgraded by its manufacturers. Mor Naaman, a professor of information science at Cornell Tech, agrees that publishers won't stand a chance in detecting AI-generated books soon. He notes that AI learns quickly how to avoid detection and that the line between human and AI-generated content is becoming increasingly blurred. The debate raises questions about the role of AI in creative writing and the importance of trust between readers and writers. Anna Ganley, of the Society of Authors, launched the Human Authored scheme to identify works written by humans, but it relies on trust, a value that is inherently vulnerable. Amelia Hill, the author of the article, highlights the importance of preserving the human element in literature, stating that AI may flood the market with content, but it cannot replace the messy, difficult work of being human.